We use some essential cookies to make this website work.
We’d like to set additional cookies to understand how you use GOV.UK, remember your settings and improve government services.
We also use cookies set by other sites to help us deliver content from their services.
You have accepted additional cookies. You can change your cookie settings at any time.
You have rejected additional cookies. You can change your cookie settings at any time.
Departments, agencies and public bodies
News stories, speeches, letters and notices
Detailed guidance, regulations and rules
Reports, analysis and official statistics
Consultations and strategy
Data, Freedom of Information releases and corporate reports
Register to vote Register by 18 June to vote in the General Election on 4 July.
How to account for VAT on goods and services provided by registered health professionals, including doctors, dentists, nurses and pharmacists.
How to apply for a clinical trial including eligibility, phases, model IMPDs, costs and how to make changes to your application.
Find out when it's possible to get zero-rated supplies on medical and research goods and services that have been funded by charities.
Clarification for the interpretation of the new elements within the Veterinary Medicines Regulations (VMRs), as amended, relating to combating antimicrobial resistance (AMR).
What happens if you're given a community sentence or community service. Find out about Community Payback and the rules of your community sentence.
Information for patients, healthcare professionals and developers of new medicines
Section (4A.01 - 4A.31) last updated October 2023.
Upper Tribunal Administrative Appeals Chamber decision by Judge Church on 15 August 2023.
Work out the VAT liability of goods and services supplied by health and care institutions and providers of non residential care to children.
The controls that apply if you transport waste out of or into England.
Past and current clinical trials into therapeutic and antiviral treatments for COVID-19, how to take part, and which treatments have proven to be effective.
The Medicines and Healthcare products Regulatory Agency (MHRA) has today (11 March 2024) approved the medicine quizartinib (Vanflyta) to be used alongside chemotherapy as first line treatment for adults who have acute myeloid leukaemia (AML).
Advice and guidance on the health needs of migrant patients for healthcare practitioners.
A new pathway supporting innovative approaches to the safe, timely and efficient development of medicines to improve patient access.
Don’t include personal or financial information like your National Insurance number or credit card details.
To help us improve GOV.UK, we’d like to know more about your visit today. Please fill in this survey (opens in a new tab).